CN Patent

CN116262136A — 以脯氨酰羟化酶为靶点治疗脱发疾病的药物

Assigned to Huashan Hospital of Fudan University · Expires 2023-06-16 · 3y expired

What this patent protects

本发明属医药技术领域，涉及治疗脱发疾病的药物，尤其是以EGLN1或EGLN3为靶点的降低EGLN1或EGLN3蛋白表达水平或蛋白活性的试剂在制备治疗脱发疾病药物中的用途。本发明经对提取的毛囊进行相关体外试验，结果显示，降低EGLN1或EGLN3表达可以促进毛囊生长、提高毛囊活性，同时可延长毛囊生长期、推迟毛囊进入退行期。本发明的降低EGLN1或EGLN3蛋白活性的制剂可用于制备治疗脱发疾病的药物。本发明所述脱发疾病包括：雄激素性秃发、斑秃、瘢痕性秃发；所述降低EGLN1或EGLN3蛋白活性的制剂，包括小分子抑制剂，抑制EGLN1或EGLN3表达和/或其活…

USPTO Abstract

本发明属医药技术领域，涉及治疗脱发疾病的药物，尤其是以EGLN1或EGLN3为靶点的降低EGLN1或EGLN3蛋白表达水平或蛋白活性的试剂在制备治疗脱发疾病药物中的用途。本发明经对提取的毛囊进行相关体外试验，结果显示，降低EGLN1或EGLN3表达可以促进毛囊生长、提高毛囊活性，同时可延长毛囊生长期、推迟毛囊进入退行期。本发明的降低EGLN1或EGLN3蛋白活性的制剂可用于制备治疗脱发疾病的药物。本发明所述脱发疾病包括：雄激素性秃发、斑秃、瘢痕性秃发；所述降低EGLN1或EGLN3蛋白活性的制剂，包括小分子抑制剂，抑制EGLN1或EGLN3表达和/或其活性的试剂，抗EGLN1或EGLN3抗体，含有编码突变的无活性或活性减弱的EGLN1或EGLN3的核苷酸序列的同源重组载体等。

Drugs covered by this patent

Patent Metadata

Patent number
CN116262136A
Jurisdiction
CN
Classification
—
Expires
2023-06-16
Drug substance claim
No
Drug product claim
No
Assignee
Huashan Hospital of Fudan University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.